Latest market price
26.19
-0.95-3.50%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.74 | Insider Own | 13.87% | Shs Outstand | 74.81M | Perf Week | 6.90% |
| Market Cap | 1.96B | Forward P/E | — | EPS next Y | -1.45 | Insider Trans | -0.31% | Shs Float | 57.33M | Perf Month | -13.59% |
| Enterprise Value | 1.64B | PEG | — | EPS next Q | -0.67 | Short Float | 18.14% | Perf Quarter | 67.35% | ||
| Income | -54.00M | P/S | 7.56 | EPS this Y | — | Short Ratio | 5.59 | Perf Half Y | 103.02% | ||
| Sales | 259.00M | P/B | 5.95 | EPS next Y | — | ROA | -8.48% | Short Interest | 10.40M | Perf YTD | 46.48% |
| Book/sh | 4.40 | P/C | 4.73 | EPS next 5Y | — | ROE | -16.37% | 52W High | 33.78 -22.47% | Perf Year | 28.01% |
| Cash/sh | 5.53 | P/FCF | — | EPS past 3/5Y | — | ROIC | -31.77% | 52W Low | 10.95 139.18% | Perf 3Y | 17.71% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 12.25% 18.84% | Gross Margin | 56.87% | Volatility | 9.66% 8.08% | Perf 5Y | -52.28% |
| Dividend TTM | — | EV/Sales | 6.32 | EPS Y/Y TTM | — | Oper. Margin | -59.24% | ATR (14) | 2.15 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 2.71 | Sales Y/Y TTM | 8.82% | Profit Margin | -20.98% | RSI (14) | 50.34 | Recom | 2.33 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.71 | EPS Q/Q | 113.56% | SMA20 | 1.31% | Beta | 1.61 | Target Price | 19.00 |
| Payout | 0.00% | Debt/Eq | 0.28 | Sales Q/Q | 7.27% | SMA50 | 4.40% | Rel Volume | 0.69 | Prev Close | 27.14 |
| Employees | 850 | LT Debt/Eq | 0.28 | Earnings | Nov 04 | SMA200 | 55.89% | Avg Volume | 2.02M | Price | 26.19 |
| IPO Date | Feb 05, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 119.30% 24.80% | Net Debt/EBITDA | — | Volume | 1,387,553 | Change | -3.50% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-14-26 | Reiterated | UBS | Neutral | $18 → $19 |
| Jan-07-26 | Reiterated | UBS | $18 | |
| Dec-15-25 | Upgrade | B of A Securities | Neutral → Buy | |
| Sep-29-25 | Initiated | Goldman Sachs | Neutral | $27 → $19 |
| Aug-15-25 | Downgrade | Citigroup | Buy → Neutral | |
| Nov-13-24 | Reiterated | BMO Capital | Outperform | $28 |
| Sep-23-24 | Reiterated | Goldman Sachs | Neutral | $23 → $27 |
| Aug-21-24 | Reiterated | Morgan Stanley | Equal Weight | $30 |
| Jul-02-24 | Initiated | Leerink | Outperform | $29 |
| Dec-19-22 | Initiated | Goldman Sachs | Neutral | $23 |
Latest News· Times ET
Oct-29-26
Oct-28-26
08:30AM
Schrödinger to Present at UBS Global Healthcare Conferencebusinesswire.com
Oct-26-26
Oct-21-26
Oct-18-26
Oct-18-2604:34AM
Oct-16-26
Oct-14-26
Oct-14-2611:05AM
Oct-12-26
02:15AM
Analyzing Teladoc Health (NYSE:TDOC) & Schrodinger (NASDAQ:SDGR)defenseworld.net
Oct-09-26
Oct-09-2608:01PM
Oct-08-26
Oct-06-26
Sep-30-26
Sep-24-26
Sep-24-2610:59AM
Company
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 259 | 256 | 208 | 217 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 111 | 113 | 75 | 76 | — | — | — | — | — | |
| Gross Profit | 147 | 143 | 132 | 141 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 132 | 136 | 140 | 136 | — | — | — | — | — | |
| Research and Development | 169 | 173 | 202 | 182 | — | — | — | — | — | |
| Other Operating Expense | -1 | 1 | -1 | 0 | — | — | — | — | — | |
| Operating Income | -154 | -167 | -209 | -177 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 101 | 65 | 24 | 220 | — | — | — | — | — | |
| Net Income Before Taxes | -53 | -102 | -186 | 43 | — | — | — | — | — | |
| Income Taxes | 1 | 1 | 1 | 2 | — | — | — | — | — | |
| Consolidated Net Income | -54 | -103 | -187 | 41 | — | — | — | — | — | |
| Net Income From Continuing Operations | -54 | -103 | -187 | 41 | — | — | — | — | — | |
| Net Income | -54 | -103 | -187 | 41 | — | — | — | — | — | |
| EPS (Recurring) | -0.74 | -1.41 | -2.57 | 0.57 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.74 | -1.41 | -2.57 | 0.57 | — | — | — | — | — | |
| EPS (Diluted) | -0.74 | -1.41 | -2.57 | 0.54 | — | — | — | — | — | |
| EBITDA | -46 | -96 | -180 | 48 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | 66.30 | — | — | — | — | — | |
| Price To Sales Ratio | 7.58 | 5.10 | 6.77 | 11.88 | — | — | — | — | — | |
| Gross Margin | 56.76 | 55.86 | 63.46 | 64.98 | — | — | — | — | — | |
| Operating Margin | -59.46 | -65.23 | -100.48 | -81.57 | — | — | — | — | — | |
| Net Margin | -20.85 | -40.23 | -89.90 | 18.89 | — | — | — | — | — | |
| Shares Outstanding | 75 | 73 | 73 | 72 | — | — | — | — | — | |
| Market Capitalization | 1,964 | 1,305 | 1,408 | 2,578 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Akinsanya Karen | Officer | Sep 17 '26 | Sale | 29.37 | 31,599 | 927,970 | 69,956 | Sep 21 |
| Akinsanya Karen | Officer | Sep 17 '26 | Option Exercise | 4.34 | 31,599 | 137,140 | 101,555 | Sep 21 |
| Jain Rachit | EVP & CFO | Jul 16 '26 | Sale | 15.60 | 875 | 13,647 | 50,877 | Jul 17 |
| Farid Ramy | President & CEO | Apr 17 '26 | Sale | 12.21 | 43,000 | 524,944 | 330,824 | Apr 17 |
| Farid Ramy | President & CEO | Apr 17 '26 | Option Exercise | 3.07 | 117,527 | 360,808 | 405,351 | Apr 17 |
| Farid Ramy | President & CEO | Apr 16 '26 | Option Exercise | 3.07 | 43,000 | 132,010 | 117,527 | Apr 17 |
| Farid Ramy | President & CEO | Apr 16 '26 | Sale | 12.33 | 43,000 | 530,233 | 330,824 | Apr 17 |
| Jain Rachit | EVP & CFO | Apr 16 '26 | Sale | 12.75 | 844 | 10,758 | 51,752 | Apr 17 |
| Herman Jenny | CAO | Mar 06 '26 | Sale | 12.84 | 608 | 7,808 | 34,804 | Mar 06 |
| Tran Yvonne | EVP, CLO & CPO | Mar 05 '26 | Sale | 12.89 | 1,094 | 14,107 | 52,683 | Mar 06 |
| Herman Jenny | CAO | Mar 05 '26 | Sale | 12.85 | 775 | 9,956 | 35,412 | Mar 06 |
| Jain Rachit | EVP & CFO | Mar 05 '26 | Sale | 12.90 | 1,631 | 21,033 | 52,596 | Mar 06 |
| Farid Ramy | President & CEO | Mar 05 '26 | Sale | 12.91 | 3,661 | 47,249 | 330,824 | Mar 06 |
| Akinsanya Karen | Officer | Mar 05 '26 | Sale | 12.90 | 1,366 | 17,625 | 69,956 | Mar 06 |
| Lorton Kenneth Patrick | EVP, CTO & COO, Software | Mar 05 '26 | Sale | 12.90 | 1,222 | 15,761 | 89,241 | Mar 06 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.